Clinical Observation Of Bushenhuatantongluo Decoction In The Treatment Of Kidney Deficiency With Phlegm-Stasis Blocking Collateral Type In Acute Stage Of Ischaemic Stroke

Objective: To evaluate the therapeutic effectiveness of the tutor’s self-prepared Bushenhuatantongluo decoction on ischemic stroke in its acute stage(kidney deficiency phlegm-stasis blocking collateral type).Methods: Based on the review of literature and the tutor’s clinical experience,the preset effective rate was 93% for the treatment group and 64% for the control group,and the sample size was estimated by using PASS15.0 software,combined with a 10%shedding rate,resulting in a sample size of 64 cases for this study.Sixty-four inpatients who met the criteria in the Department of Encephalopathy of Rizhao Traditional Chinese Medicine Hospital from January 2022 to December 2022 were collected,and general data such as age,gender,past history,personal history,and vital signs were collected before enrollment.The randomized group technique was employed using the SPSS 26.0 program,with a length of 4 and a number of 2 groups,and a ratio of 1:1 between the two groups,which were separated into the control group(32 cases)and the treatment group(32 cases).The treatment group received Bushenhuatantongluo decoction on the basis of the control group,and the duration of therapy was 14 days in both groups.The control group received conventional medical treatment(i.e.,antiplatelet,lipid-lowering,and symptomatic treatment)in Western medicine.The NIHSS score,BI index,TCM kidney deficiency,phlegm and phlegm stasis obstruction syndrome score were observed before and after treatment in both groups,and both groups’ adverse responses and safety indicators(ECG,blood tests,coagulation index,liver and kidney function,urine routine test,stool routine test)were kept under close observation.The data obtained were compiled using EXCEL software and analyzed using SPSS 26.0 software.Two-sided tests were used for the statistical analyses of the test data,and a statistically significant threshold of P<0.05 was employed.Results:In this study,64 cases total —32 cases in the treatment group and 64 cases in the control group—were gathered.There were no instances of rejection or shedding.1.Comparison of general conditions: the distribution of NIHSS score,BI index,Chinese medicine renal deficient phlegm,sex,age,consumption of alcohol,tobacco,cardiovascular disease,hypertension,diabetes mellitus,and hyperlipidemia between the two groups before treatment.Before treatment,the two groups’ differences in NIHSS scores,BI index,and TCM symptoms of phlegm deficiency and phlegm blockage were all assessed at P values > 0.05,indicating that there was no objectively substantial difference among the two groups in terms of general circumstances.2.Chinese medicine efficacy observation index:pre-treatment differences between the two groups were not statistically significant(P>0.05);post-treatment differences between the two groups were comparable(P<0.01);pre-and post-treatment differences were statistically different(P<0.05);Phlegm,stasis obstruction,and renal deficiency symptoms all improved at a total effective rate of 96.88% in the treatment group compared to a total effective rate of 53.13% in the comparison group for the same symptoms.3.Western medicine efficacy observation index: both the treatment group and the control group had lower NIHSS scores,and both groups’ BI indices improved,indicating that both groups may have been able to lessen the severity of neurological impairments and enhance capacity for self-care.Before to treatment,there was no statistically noteworthy distinction among the two groups’ NIHSS scores(P>0.05);however,following treatment,the difference between the treatment group and the control group was comparable(P<0.01).The difference between the two groups’ NIHSS scores before and after therapy was positively accurate(P<0.05);the treatment group’s overall effective rate of improvement was 93.75%,while the control group’s mean cumulative rate of improvement was 87.5%.Beforre treatment,there was no statistically noteworthy distinction between the treatment group and the control group(P>0.05);after treatment,there was no statistically significant distinction between the treatment group and the control group(P<0.05);there was a statistical significance noteworthy distinction among the two groups before and after treatment(P<0.05);and there was a statistically significant difference between the two groups’ BI index efficacy before and after treatment(P<0.05).4.When the two groups’ pre-and post-14-day changes in blood normal,blood coagulation,liver,and kidney function indices were compared within each group,the P values were >0.05,indicating that the differences within each group were not similar.During the research period,there were no negative effects.Conclusion:Bushenhuatantongluo decoction has better efficacy than Western medical internal medicine treatment alone in improving the TCM clinical signs,level of neurological impairment and ability of daily living of patients with ischemic stroke acute phase with kidney deficiency,phlegm and phlegm blocking evidence;Bushenhuatantongluo decoction has no toxic side effects and is safe and worthy of further clinical application.